Australian Paediatric Surveillance Unit

PAEDIATRIC INFLAMMATORY MULTISYSTEM SYNDROME **TEMPORALLY ASSOCIATED WITH SARS-COV-2**

Please contact the APSO by email <u>SCHN-APSO@neaith.nsv</u>	<u>v.gov.au</u> If ye	u nave any quest	ions about this form			
<u>Instructions</u> : Please answer each question by ticking the appropriate box or writing your response in the space provided. DK=Don't Know; NA = Not Applicable.					7/02/2023	
PIMS-TS CASE DEFINITION (please tick all that app	ply)					
Children and adolescents (up to 18 years of age) with fermal Rash or bilateral non-purulent conjunctivitis or murange Age specific hypotension or "shock" within first 24 Features of myocardial dysfunction, pericarditis, and Troponin/NT-proBNP), Evidence of coagulopathy (by PT, PTT, elevated d-Acute gastrointestinal problems (diarrhoea, vomit Elevated markers of inflammation such as ESR, C-Exclusion of other infectious causes of inflammat syndromes AND Evidence of SARS-CoV-2 infection including one or 2 serology (noting testing may be delayed, particular OR contact with a confirmed COVID-19 case.	ever ≥3 danuco-cutane 4 hours of valvulitis, of Dimers) ting, or aboureactive pro ion, includer more of:	eous inflamma presentation or coronary ab dominal pain) A rotein, or proca ling bacterial so	tion signs (oral, hands of onormalities (including E AND alcitonin AND epsis, staphylococcal or R or antigen test or conf	ECHO findings of streptococcal firmed positive	toxic shock SARS-CoV-	
REPORTING CLINICIANS DETAILS						
Dr Name:		Phone:				
APSU Code (if known):		Email:				
		Date case rep	ort form			
Hospital:		completed:/				
Has this child been reported via PAEDS?		Yes	No Don't Know	1		
PATIENT DETAILS						
First 2 letters of first name:						
First 2 letters of surname:						
Date of Birth:	/_					
Sex:	Male	5	Female			
Postcode of family:						
Country of birth:	Aust	ralia	Other, specify:			
Is the child of Aboriginal or Torres Strait Islander		riginal	Torres Strait Island	der		
origin?	Both	n Aboriginal an	d Torres Strait Islander			
, , , , , , , , , , , , , , , , , , ,	☐ No	☐ No ☐ Don't know				
Mother's country of birth:						
Father's country of birth:					DK	
SECTION 2: Medical History						
Was the child born pre-term (<37 weeks)?	Yes	☐ No	Unknown			
Does the child have a history of:						
- Airway/respiratory disease?	Yes	☐ No	Unknown			
If Yes, specify:						
- Cardiac disease?	Yes	☐ No	Unknown			
<i>If Yes,</i> specify:			· 			
- Neurological disease?	Yes	☐ No	Unknown			
If Yes, specify:						
- Immunodeficiency or immunocompromised?	Yes	☐ No	Unknown			

If Yes, specify:

APSU Office Use Only

Study ID #:

- Diabetes?			Yes	☐ No	Unkı	nown	
- Other significant medical history?			Yes	☐ No	Unkı	nown	
If Yes, specify:		_					
		_					
SECTION 3: Vaccination History							
COVID-19 Vaccination History							
How many doses of COVID-19 vaccine has th received?	e child		None	1	2	☐ 3 ☐	Unknown
COVID-19 vaccine dose 1 brand:			_	naty (Pfize ax (Moder wn	-		
Date of COVID-19 vaccine dose 1:		_	/_	_/			
COVID-19 vaccine dose 2 brand:				naty (Pfize ax (Moder wn	-		
Date of COVID-19 vaccine dose 2:		_	/	_/			
COVID-19 vaccine dose 3/booster brand:		[]]	=	naty (Pfize ax (Moder wn	-		
Date of COVID-19 vaccine dose 3/booster da	ite:	_	_ /	_/			
Additional comments:		_					
SECTION 5: Presentation							
Presenting Clinical Features							
Date of onset of first symptom or sign? (associated with suspected PIMS-TS)		/	_/				
Date of onset of fever (≥38.0 °C):		/	_/	 all that ap	_1_	1111	
Clinical Feature	ГП						it present:
Rash		Yes	∐ No		Unknown	At onset	At any time
Breathing difficulty		Yes	∐ No		Unknown	At onset	At any time
Abdominal pain		Yes			Unknown	At onset	At any time
Diarrhoea		Yes	N		Unknown	At onset	At any time
Vomiting		Yes			Unknown	At onset	At any time
Oedema		Yes	No		Unknown	At onset	At any time
Joint pain		Yes	No) <u> </u>	Unknown	At onset	At any time
Muscle pain		Yes	No) <u> </u>	Unknown	At onset	At any time
Headache		Yes	∐ No) <u></u>	Unknown	At onset	At any time
Anosmia (loss of smell)		Yes	□ No) []	Unknown	At onset	At any time
Hypogeusia (loss of taste)		Yes	☐ No) []	Unknown	At onset	At any time
Conjunctival injection		Yes	□ No) <u> </u>	Unknown	At onset	At any time
Mucosal changes (strawberry tongue, red lips, pharyngeal erythema)		Yes	□ No) <u> </u>	Unknown	At onset	At any time
Peripheral cutaneous inflammation signs (hands & feet)		Yes	□ No) <u> </u>	Unknown	At onset	At any time
Lymphadenopathy		Yes	No		Unknown	At onset	At any time
Shock		Yes	□ No		Unknown	At onset	At any time
Age specific hypotension		Yes	□ No		Unknown	At onset	At any time
Additional comments Any significant information relating to presentation that is not captured above?							

SECTION 6: SARS-CoV-2 & Pathoge	n Testing		
SARS-CoV-2 Testing			
Polymerase chain reaction (PCR) assay:	Positive	Negative	Not done
Date of PCR:	//		
Rapid Antigen Test (RAT):	Positive	□ Negative	Not done
Date of RAT:	//		
COVID-19 test (unknown if PCR or RAT):	Positive	Negative	Not done
Date of COVID-19 test (Unknown if PCR or			
SARS-CoV-2 NCP Ab Test:	Positive	Negative	Indeterminant
Date of SARS-CoV-2 NCP Ab Test:	/	Negative	Indeterminant
SARS-CoV-2 Spike Ab Test: Date of SARS-CoV-2 Spike Ab Test:	Positive	Negative	
Other SARS-CoV-2 assay (e.g. ELISA, neutr	ralisation Positive	Negative	Not done
test)			
Specify other SARS-CoV-2 assay: (Test type. site of specimen, titre)			
Date of other SARS-CoV-2 assay:	//		
Co-pathogen detection	•		
Were any other pathogens detected?	∏Yes ∏No		
(other than SARS-CoV-2)			
Date of sample:	//		
State pathogen:			
SECTION 7: Investigations			
Chest imaging			
Was chest x-ray performed?	☐ Yes ☐ No	Unknown	
(standard chest x-ray - not CT or MRI)			
<i>If yes</i> , findings (copy & paste repor	rt		
conclusions):			
Was other chest imaging performed? (e.g. CT or MRI of the chest)	Yes No	Unknown	
Specify the details of other chest imaging:			
(date, type of chest imaging, conclusions)			
Haematology			
Please record the worst available results in	the first 7 days.		
Test	Requested	I	Result
Haemoglobin assay	Yes No	t done	(g/L)
White cell count	Yes No	t done	(x10^9/L)
Platelet count	Yes No	t done	(x10^9/L)
Neutrophil count	Yes No	t done	(x10^9/L)
Lymphocyte count	Yes No	t done	(x10^9/L)
Monocyte count	☐ Yes ☐ No	t done	(x10^9/L)
Eosinophil count	☐ Yes ☐ No	t done	(x10^9/L)
Fibrinogen	Yes No	t done	(g/L)
d-Dimer	Yes No	t done	(ng/mL)
Prothrombin time	Yes No	t done	(seconds)
Erythrocyte sedimentation rate (ESF	R) Yes No	t done	(mm/hour)

Biochemistry

Please record the worst available results in the first 7 days.

Test	Re	equested	Result
Urea	Yes	Not done	(mmol/L)
Creatinine	Yes	Not done	(IU/L)
Alanine Aminotransferase (ALT)	Yes	Not done	(IU/L)
Aspartate aminostransferase (AST)	Yes	Not done	(IU/L)
Gamma-glutamyl transferase (GGT)	Yes	Not done	(IU/L)
Bilirubin	Yes	Not done	(umol/L)
Albumin	Yes	Not done	(umol/L)
C Reactive Protein (CRP)	Yes	Not done	(mg/L)
Procalcitonin (PCT)	Yes	Not done	(ng/mL)
Ferritin	Yes	Not done	
		Not done	(mcg/L)
Troponin T Troponin I	Yes Yes	Not done	(ng/L) (ng/L)
Brain natriuretic peptide (BNP)	Yes	Not done	(ng/L) (pg/mL)
NT-pro-BNP	Yes	Not done	(pg/mL)
Lactate dehydrogenase (LDH)	Yes	Not done	(IU/L)
Creatine Kinase (CK)	Yes	Not done	(IU/L)
Soluble interleukin-2 receptor (sCD-25)	Yes	Not done	(IU/L)
If yes, was it: If abnormal, was there:	Norma Abnor Unkno	rmal	
Additional comments Any significant information relating to investigations that was not captured above	Myoca	ardial dysfunction	
ECTION 8: Treatment and Supportive Care			
reatment Which of the following treatments did the child recei - Antibiotics:	ve?	☐ No	
<i>If Yes</i> , specify:	Oral	Parenteral (IM/IV)	
- Antivirals: **If Yes, specify:**	Yes	No	
Corticosteroids:	Yes	☐ No	
<i>If Yes</i> , specify:	☐ Oral ☐ Inhale	Parenteral (IM/IV) d Topical	
Specify route:			
Specify corticosteroid maximum daily dose:			
Intravenous immunoglobulin (IVIG):	Yes	∐ No	
Specify other brand of IVIG:			
Specify IVIG dose: Number of days of IVIG treatment:			(grams/ round up da

- Aspirin:	Yes No		
Dose:	(mg/k	g)	
- Anticoagulants?	Yes No		
If Yes, specify anticoagulant: Specify route: - Specify other specific treatment(s): (specify treatment, route & dose)	Oral Parenteral (IM/IV)		
Supportive care - including intensive care support Was the child admitted to intensive care or high dependency unit? (ICU or HDU) Date of ICU admission: Date of ICU discharge:	☐ Yes ☐ No // //		
Highest level of respiratory support required:	 □ Invasive ventilation □ Non-invasive ventilation CPAP or BiPAP □ High flow nasal prongs □ None of the above (During ICU admission) 		
Unit of oxygen supplementation:	Oxygen (L/min)FiO2 oxygen (%)No oxygen (During ICU admission)		
At any time during this illness did the child receive? Inotropes/vasopressors: If yes, specify the inotrope/vasopressor(s):	Yes No Unknown	_	
Extracorporeal (ECMO) support:	Yes No Unknown		
Plasma exchange:	Yes No Unknown		
Blood transfusion:	Yes No Unknown		
Additional Comments Any significant information relating to treatment or supportive care that was not captured above			
SECTION 9: Discharge & Case Completion			
What was the child's discharge status?	□ Discharged□ Transferred to other hospital□ Still hospitalised at 60 days□ Deceased*		
Date of death	//		
Date of discharge or hospital transfer	//		
Length of stay (days)			

Thank you for your help with this research project.

Please return this case report form to the APSU via email to <u>SCHN-APSU@health.nsw.gov.au</u> or fax to 02 9845 3082, or mail to Australian Paediatric Surveillance Unit, Kids Research, Locked Bag 4001, Westmead NSW 2145 - even if you don't complete all items.

The APSU is affiliated with the Royal Australasian College of Physicians (Paediatrics and Child Health Division) and Faculty of Medicine and Health, The University of Sydney.

The APSU is funded by the Australian Government Department of Health.

This study has been approved by a Human Research Ethics Committee properly constituted under NHMRC guidelines.